ScienceDex / Researcher record
Leif W Ellisen
- Massachusetts General Hospital · Internal Medicine (investigator's affiliation)
- Dana-Farber Cancer Institute (no department on record)
From the FY2026 NIH awards this investigator leads as contact PI. The department is the award's.
FY2026 NIH rank #2,126
- Program Leader
- R01 Holder
- Early Career
NIH Funding · FY2026
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
Linked awards ($M)Award-linked rank
View yearly values
| Fiscal year | Linked awards | Records | Rank |
|---|---|---|---|
| 2024 | $1,968,638 | 4 | #5,515 |
| 2025 | $2,182,246 | 4 | #5,813 |
| 2026 | $5,951,776 | 4 | #2,126 |
Award activity
Awards through the years
NIH award records listing this researcher in each fiscal year.
- FY20244 records
- FY20254 records
- FY2026 · selected4 records
Each bar starts at zero. Annual records can include renewals of the same project; they are not a count of distinct career grants.
Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 1980799Search this ID in NIH RePORTER
- ORCID iD
- https://orcid.org/0000-0003-0444-7910Verified identifier for this researcher
- ScienceDex PI coverage
- FY2024 through FY2026Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2027.
FY2026 award records by amount
NIH award records listing Leif W Ellisen as a PI. Multi-PI records show the full award amount for context.
- 5P50CA168504-12P50Contact PIDana Farber/Harvard Cancer Center Specialized Program of Research Excellence in Breast Cancer$2.5Maward amount
- 4R01CA294793-03R01Co-investigatorElucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancerMassachusetts General Hospital · Internal Medicine (investigator's affiliation)$2.1Maward amount
- 5R01CA248923-05R01Contact PISubclonal heterogeneity and outcome disparities in Triple-Negative Breast Cancer among African AmericansMassachusetts General Hospital · Internal Medicine (investigator's affiliation)$784.1Kaward amount
- 5R01CA260890-05R01Contact PISynergistic combinatorial DNA damage response/repair inhibition and Sacituzumab Govitecan in triple-negative breast cancerMassachusetts General Hospital · Internal Medicine (investigator's affiliation)$559.8Kaward amount
Award organizations
Organizations that administered FY2026 awards listing Leif W Ellisen as a PI.
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardMassachusetts General Hospital
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2024Entered Top 50% NationallyRanked #5515
- 2025$2M Cumulative Funding
- 2025Multi-Institutional ResearchAwards at 2 institutions
- 2025R01 Grant Holder
- 2025Program/Center Grant Leader
- 2026$5M Cumulative Funding
- 2026$10M Cumulative Funding
- 2026Entered Top 25% NationallyRanked #2126
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Leif W Ellisen.
Aditya Bardia
Massachusetts General Hospital
3
shared awards
Naomi Yu Ko
Massachusetts General Hospital
3
shared awards
Priscilla Kaliopi Brastianos
Massachusetts General Hospital
3
shared awards
Deborah A. Dillon
Dana-Farber Cancer Institute
2
shared awards
Geoffrey I. Shapiro
Dana-Farber Cancer Institute
2
shared awards
Judy E. Garber
Dana-Farber Cancer Institute
2
shared awards
Kornelia Polyak
Dana-Farber Cancer Institute
2
shared awards
Myles A Brown
Dana-Farber Cancer Institute
2
shared awards
Nabihah Tayob
Dana-Farber Cancer Institute
2
shared awards
Nancy U Lin
Dana-Farber Cancer Institute
2
shared awards